Preventing lung cancer by targeting a new drug to mitochondria
Chemoprevention of lung cancer by targeting lonidamine to mitochondria
['FUNDING_R01'] · METHODIST HOSPITAL RESEARCH INSTITUTE · NIH-10687020
This study is testing a new drug called Mito-LON to see if it can help stop lung cancer by targeting the energy centers of cancer cells, and it's designed for people who are concerned about lung cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | METHODIST HOSPITAL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10687020 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new drug, Mito-LON, aimed at preventing lung cancer by targeting the mitochondria of cancer cells. The approach involves modifying an existing compound to enhance its effectiveness in inhibiting cancer cell growth and spread. By studying how Mito-LON affects the energy production and survival of lung cancer cells, researchers aim to understand its potential to induce cell death specifically in tumors. The research includes laboratory experiments to evaluate the drug's impact on cancer cell metabolism and growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, such as smokers or those with a family history of the disease.
Not a fit: Patients who already have advanced lung cancer or those with other types of malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel preventive treatment for lung cancer, potentially reducing the incidence and mortality associated with this disease.
How similar studies have performed: Other research has shown promise in targeting mitochondrial functions for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
HOUSTON, UNITED STATES
- METHODIST HOSPITAL RESEARCH INSTITUTE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YOU, MING — METHODIST HOSPITAL RESEARCH INSTITUTE
- Study coordinator: YOU, MING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer